Regeneron Pharmaceuticals Inc. logo

Regeneron Pharmaceuticals (REGN) stock

REGN · Regeneron Pharmaceuticals Inc. · NASDAQ

Website
Market cap
$95.30B
P/E
20.4
EPS (TTM)
$45.21
Shares out
103.4M
52-week range83% up the range
$591.65$988.48

What is the latest news on REGN stock?

REGN fell 0.26% to $921.22 on Nov 20, 2026. No REGN story in the last two days; the most recent is below.

SECago
SEC Form S-8 filed by Regeneron Pharmaceuticals Inc.

S-8 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

All REGN news
Price$921.22-0.28 (-0.03%)
07:15 PM08:45 PM

Who owns the most REGN stock?

BlackRock, Inc. was the largest reported holder of REGN at the end of Q2 2026, with 9,113,506 shares worth $5.7 billion. Next came Vanguard Capital Management LLC ($4.1 billion) and Dodge & Cox ($3.0 billion). In all, 1,332 institutions reported $57.2 billion of REGN in their 13F filings.

All REGN fund holders

Are insiders buying or selling REGN?

Insiders are selling. In the last 90 days 9 insiders sold $56.0 million of REGN in trades reported on Form 4. The latest: George L Sing sold $1.9 million, reported on Nov 18, 2026.

REGN insider trades

Financial highlights

Full financials
Revenue, TTM
$16.90B
Revenue growth
+18.6%
Net income, TTM
$4.82B
Net margin
28.5%
Free cash flow, TTM
$3.83B
Cash
$3.66B

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

Latest news

25 items

REGN rankings

News · 26 weeks58+144%
2026-05-31: 02026-06-07: 02026-06-14: 12026-06-21: 22026-06-28: 02026-07-05: 22026-07-12: 02026-07-19: 12026-07-26: 32026-08-02: 12026-08-09: 22026-08-16: 52026-08-23: 12026-08-30: 22026-09-06: 02026-09-13: 02026-09-20: 12026-09-27: 62026-10-04: 22026-10-11: 32026-10-18: 02026-10-25: 42026-11-01: 122026-11-08: 22026-11-15: 82026-11-22: 0
2026-05-312026-11-22
Mix4190d
  • Insider16(39%)
  • Other15(37%)
  • SEC Filings5(12%)
  • Earnings4(10%)
  • Analyst1(2%)
Activity · 52 weeks16292 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Our reporting on REGN

Regeneron Pharmaceuticals Inc. (REGN) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 26 wire items for REGN, including 13 insider trades, 9 press releases and news items and 3 SEC filings. The most recent was published Nov 19, 2026.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

REGN FAQ

11 questions
  • What does Regeneron Pharmaceuticals Inc. do?
    Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults...
  • What is REGN revenue?
    Regeneron Pharmaceuticals Inc. (REGN) reported $16.90B of revenue for the twelve months ended Sep 30, 2026. That is up 18.6% from the year before. Revenue for fiscal 2025 was $14.34B.
  • Is REGN profitable?
    Yes. Regeneron Pharmaceuticals Inc. earned $4.82B in net income for the twelve months ended Sep 30, 2026, a net margin of 28.5%.
  • How much cash and debt does REGN have?
    Regeneron Pharmaceuticals Inc. reported $3.66B in cash and cash equivalents and $1.99B of debt on its most recent balance sheet in SEC filings.
  • Where does REGN stock trade?
    Regeneron Pharmaceuticals Inc. (REGN) is listed on NASDAQ.
  • What sector and industry is REGN in?
    Regeneron Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Regeneron Pharmaceuticals Inc. go public?
    Regeneron Pharmaceuticals Inc. (REGN) completed its IPO in 1991.
  • Does REGN pay a dividend?
    REGN's most recent ex-dividend date was 2026-11-20 with a cash dividend of $0.94 per share. No future ex-date is on file yet.
  • What are analysts saying about REGN?
    Across the last 8 analyst actions on Regeneron Pharmaceuticals Inc., there were 2 upgrades and 3 downgrades. The most recent action was from Argus: Buy with a $850.00 price target on 2026-10-01. Recent price targets range from $641.00 to $923.00.
  • What companies are similar to REGN?
    Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), GILD (Gilead Sciences Inc.), AMGN (Amgen Inc.), VRTX (Vertex Pharmaceuticals Incorporated). Compare REGN side-by-side with any of them on Quantisnow.
  • How can I track REGN on Quantisnow?
    Quantisnow aggregates Regeneron Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow REGN to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change